245 related articles for article (PubMed ID: 21154135)
1. Alzheimer's Disease Drug Discovery--11th International Conference--Targeting Pathological Tau. 27-28 September 2010, Jersey City, NJ, USA.
Wolfe MS
IDrugs; 2010 Dec; 13(12):828-9. PubMed ID: 21154135
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's Disease Drug Discovery--11th International Conference--Promising New Therapeutic Approaches. 27-28 September 2010, Jersey City, NJ, USA.
Wolfe MS
IDrugs; 2010 Dec; 13(12):825-7. PubMed ID: 21154134
[TBL] [Abstract][Full Text] [Related]
3. Dementia Therapy Targeting Tau.
Buee L
Adv Exp Med Biol; 2019; 1184():407-416. PubMed ID: 32096053
[TBL] [Abstract][Full Text] [Related]
4. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.
Brunden KR; Trojanowski JQ; Lee VM
Nat Rev Drug Discov; 2009 Oct; 8(10):783-93. PubMed ID: 19794442
[TBL] [Abstract][Full Text] [Related]
5. The 14th International Conference on Alzheimer's Drug Discovery, 9 - 10 September 2013, in Jersey City, New Jersey.
Glicksman MA
Expert Opin Drug Discov; 2014 Feb; 9(2):215-20. PubMed ID: 24444088
[TBL] [Abstract][Full Text] [Related]
6. Modulating Protein Phosphatase 2A Rescues Disease Phenotype in Neurodegenerative Tauopathies.
McKenzie-Nickson S; Chan J; Perez K; Hung LW; Cheng L; Sedjahtera A; Gunawan L; Adlard PA; Hayne DJ; McInnes LE; Donnelly PS; Finkelstein DI; Hill AF; Barnham KJ
ACS Chem Neurosci; 2018 Nov; 9(11):2731-2740. PubMed ID: 29920069
[TBL] [Abstract][Full Text] [Related]
7. Current strategies for the treatment of Alzheimer's disease and other tauopathies.
Dickey CA; Petrucelli L
Expert Opin Ther Targets; 2006 Oct; 10(5):665-76. PubMed ID: 16981824
[TBL] [Abstract][Full Text] [Related]
8. AlphaScreen Identifies MSUT2 Inhibitors for Tauopathy-Targeting Therapeutic Discovery.
Baker JD; Uhrich RL; Strovas TJ; Saxton AD; Kraemer BC
SLAS Discov; 2021 Mar; 26(3):400-409. PubMed ID: 32981422
[TBL] [Abstract][Full Text] [Related]
9. Targeting tau: Clinical trials and novel therapeutic approaches.
VandeVrede L; Boxer AL; Polydoro M
Neurosci Lett; 2020 Jul; 731():134919. PubMed ID: 32380145
[TBL] [Abstract][Full Text] [Related]
10. A walk through tau therapeutic strategies.
Jadhav S; Avila J; Schöll M; Kovacs GG; Kövari E; Skrabana R; Evans LD; Kontsekova E; Malawska B; de Silva R; Buee L; Zilka N
Acta Neuropathol Commun; 2019 Feb; 7(1):22. PubMed ID: 30767766
[TBL] [Abstract][Full Text] [Related]
11. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.
Lasagna-Reeves CA; Castillo-Carranza DL; Jackson GR; Kayed R
Curr Alzheimer Res; 2011 Sep; 8(6):659-65. PubMed ID: 21605039
[TBL] [Abstract][Full Text] [Related]
12. Impaired tau-microtubule interactions are prevalent among pathogenic tau variants arising from missense mutations.
Xia Y; Sorrentino ZA; Kim JD; Strang KH; Riffe CJ; Giasson BI
J Biol Chem; 2019 Nov; 294(48):18488-18503. PubMed ID: 31653695
[TBL] [Abstract][Full Text] [Related]
13. Recent developments in tau-based therapeutics for neurodegenerative diseases.
Medina M
Recent Pat CNS Drug Discov; 2011 Jan; 6(1):20-30. PubMed ID: 21118095
[TBL] [Abstract][Full Text] [Related]
14. Recent developments with tau-based drug discovery.
Iqbal K; Liu F; Gong CX
Expert Opin Drug Discov; 2018 May; 13(5):399-410. PubMed ID: 29493301
[TBL] [Abstract][Full Text] [Related]
15. An Overview on the Clinical Development of Tau-Based Therapeutics.
Medina M
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29641484
[TBL] [Abstract][Full Text] [Related]
16. Tau immunotherapy for Alzheimer's disease.
Pedersen JT; Sigurdsson EM
Trends Mol Med; 2015 Jun; 21(6):394-402. PubMed ID: 25846560
[TBL] [Abstract][Full Text] [Related]
17. Tau pathology in Alzheimer disease and other tauopathies.
Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
[TBL] [Abstract][Full Text] [Related]
18. Tau protein aggregation: Key features to improve drug discovery screening.
Giovannini J; Smeralda W; Jouanne M; Sopkova-de Oliveira Santos J; Catto M; Voisin-Chiret AS
Drug Discov Today; 2022 May; 27(5):1284-1297. PubMed ID: 35085785
[TBL] [Abstract][Full Text] [Related]
19. Invited review: Drug development for tauopathies.
Grüninger F
Neuropathol Appl Neurobiol; 2015 Feb; 41(1):81-96. PubMed ID: 25354646
[TBL] [Abstract][Full Text] [Related]
20. A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies.
Zheng J; Tian N; Liu F; Zhang Y; Su J; Gao Y; Deng M; Wei L; Ye J; Li H; Wang JZ
Signal Transduct Target Ther; 2021 Jul; 6(1):269. PubMed ID: 34262014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
